Downstream Therapeutics has developed an innovative combination drug-device aimed at mitigating cell injury following the restoration of blood flow. This technology integrates a clinically validated drug with a novel drug delivery system, enhancing the recovery process for patients who have experienced a loss of blood flow. By facilitating a more effective treatment approach, this technology not only accelerates patient recovery but also aims to reduce long-term disability, ultimately leading to better patient outcomes.

Currently, the company is in the research and development phase, actively seeking funding to advance their project towards FDA approval. The focus is on completing the necessary research and the initial testing phases to validate the efficacy and safety of their drug-device combination. Downstream Therapeutics is committed to improving patient care and reducing future healthcare costs through their innovative approach to treatment.

United States

Downstream Therapeutics is a biotechnology company that focuses on developing a combination drug-device to reduce cell injury after restoration of blood flow.

Downstream Therapeutics

Company Details